カテゴリ： GlobalData, イギリス, 企業調査

Abzena Plc (ABZA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Abzena Plc (ABZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8111
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：67
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company’s technologies include antibody discovery and candidate screening, immunology and immunogenicity assessment, manufacture of payload linkers and antibody drug conjugates, development of manufacturing cell lines and process development, and others. Abzena provides its services to biopharmaceutical companies, public and private biotech companies and academic groups, among others. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.

Abzena Plc (ABZA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Abzena Raises Funds through Venture Financing 14
Partnerships 16
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Licensing Agreements 30
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Equity Offering 40
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Acquisition 44
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc – Key Competitors 50
Abzena Plc – Key Employees 51
Abzena Plc – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Joint Venture 53
Recent Developments 54
Strategy And Business Planning 54
Jan 05, 2018: Abzena Takes on New Facilities in Cambridge, UK and San Diego 54
Financial Announcements 55
Apr 16, 2018: Abzena: Pre-Close Period Trading Update FY2018 55
Dec 12, 2017: Half year results: Growth strategy progressing 57
Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 58
Feb 21, 2017: Abzena: Trading and business update 59
Corporate Communications 61
Oct 16, 2018: Abzena announces the appointment of Jonathan Goldman, MD as Chief Executive Officer 61
Legal and Regulatory 62
Mar 05, 2018: Abzena: Settlement of claim 62
Government and Public Interest 63
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 63
Product News 64
Mar 06, 2017: ‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial 64
Other Significant Developments 65
Mar 26, 2018: Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite 65
Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Raises Funds through Venture Financing 14
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc, Key Competitors 50
Abzena Plc, Key Employees 51
Abzena Plc, Other Locations 52
Abzena Plc, Subsidiaries 52
Abzena Plc, Joint Venture 53

List of Figures
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Abzena Plc (ABZA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Nippon Kayaku Co., Ltd.：企業の戦略・SWOT・財務情報
    Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sensus Healthcare Inc (SRTS)：企業の製品パイプライン分析2018
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Vietnam National Oil and Gas Group-エネルギー分野：企業M&A・提携分析
    Summary Vietnam National Oil and Gas Group (Petrovietnam) is an oil and gas organization that offers oil and gas exploration and development services. The organization's services include oil and natural gas exploration and production, petroleum and financial services, processing of petrochemicals, r …
  • Duke Energy Corp：企業の発電所・SWOT分析2018
    Duke Energy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Biomay AG-製薬・医療分野：企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • Allscripts Healthcare Solutions Inc (MDRX)：企業の財務・戦略的SWOT分析
    Allscripts Healthcare Solutions Inc (MDRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Aerojet Rocketdyne Holdings Inc：企業の戦略・SWOT・財務情報
    Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Aerojet Rocketdyne Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • University of Rochester-製薬・医療分野：企業M&A・提携分析
    Summary University of Rochester (UOR) is an educational university that offers research and development services. The university performs research in the areas of humanities, engineering medical education, medicine, geology, optics, economics, political theory, human behavior, and social and natural …
  • EnWave Corp (ENW)-製薬・医療分野：企業M&A・提携分析
    Summary EnWave Corp (EnWave) is an advanced technology company that provides industrial-scale dehydration technology for commercial applications in the pharmaceutical and food industries. It designs, constructs, markets and sells microwavevacuum biomaterial and food dehydration machines that use pro …
  • Electricite de France SA (EDF)-石油・ガス分野：企業M&A・提携分析
    Summary Electricite de France S.A. (EDF) is a state-owned integrated energy company that generates, transmits, distributes and sells electricity; supplies natural gas; and offers energy services such as district heating, thermal energy services and other services. The group generates electricity fro …
  • SM Energy Co (SM)：石油・ガス：M&Aディール及び事業提携情報
    Summary SM Energy Co (SM Energy) is an independent upstream oil and gas company. It carries out the acquisition, exploration, development, and production of crude oil, natural gas and natural gas liquids (NGLs) in onshore North America. The company’s operations are concentrated in three onshore oper …
  • Marksmen Energy Inc (MAH)：石油・ガス：M&Aディール及び事業提携情報
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, mines, manages, produces and develops oil and gas properties in Western …
  • Krung Thai Bank PCL：企業の戦略・SWOT・財務分析
    Krung Thai Bank PCL - Strategy, SWOT and Corporate Finance Report Summary Krung Thai Bank PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Boehringer Ingelheim GmbH-医療機器分野：企業M&A・提携分析
    Summary Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer healt …
  • Rizzani De Eccher S.P.A.
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Immatics Biotechnologies GmbH：企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • OSI Systems, Inc. (OSIS)：企業の財務・戦略的SWOT分析
    OSI Systems, Inc. (OSIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cytodyn Inc (CYDY)：企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed agai …
  • Northwest Pipe Co (NWPX)：企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Asure Software, Inc. (ASUR)：企業の財務・戦略的SWOT分析
    Asure Software, Inc. (ASUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆